{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Therapeutics%2C+Inc.",
    "query": {
      "sponsor": "Therapeutics, Inc.",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 2821,
    "total_pages": 283,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Therapeutics%2C+Inc.&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Therapeutics%2C+Inc.&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T03:58:23.643Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04033432",
      "title": "sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents",
        "Metastatic Prostate Adenocarcinoma",
        "Progressive Disease",
        "Prostate Carcinoma Metastatic in the Bone",
        "Prostate Carcinoma Metastatic in the Soft Tissue",
        "PSA Progression",
        "Stage IVB Prostate Cancer AJCC v8",
        "Testosterone Less Than 50 ng/dL"
      ],
      "interventions": [
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2019-09-20",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04033432"
    },
    {
      "nct_id": "NCT03998163",
      "title": "CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus"
      ],
      "interventions": [
        {
          "name": "CR845 0.5 mcg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cara Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 222,
      "start_date": "2019-05-06",
      "completion_date": "2020-03-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 33,
      "location_summary": "Escondido, California • Riverside, California • San Diego, California + 26 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03998163"
    },
    {
      "nct_id": "NCT03794206",
      "title": "Vesair Balloon Confirmatory Trial (VECTOR)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Vesair Balloon",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Solace Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 20,
      "start_date": "2019-02-11",
      "completion_date": "2022-04-28",
      "has_results": false,
      "last_update_posted_date": "2022-06-13",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 8,
      "location_summary": "Arlington Heights, Illinois • Shreveport, Louisiana • Hanover, Maryland + 5 more",
      "locations": [
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Hanover",
          "state": "Maryland"
        },
        {
          "city": "Owings Mills",
          "state": "Maryland"
        },
        {
          "city": "Poughkeepsie",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03794206"
    },
    {
      "nct_id": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Other Skin"
      ],
      "interventions": [
        {
          "name": "Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interferon Gamma-1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-07-03",
      "completion_date": "2024-01-09",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03747484"
    },
    {
      "nct_id": "NCT02341807",
      "title": "Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Choroideremia",
        "CHM (Choroideremia) Gene Mutations"
      ],
      "interventions": [
        {
          "name": "AAV2-hCHM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2015-01-15",
      "completion_date": "2022-10-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341807"
    },
    {
      "nct_id": "NCT04541628",
      "title": "Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "SIG-001",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2020-09-28",
      "completion_date": "2023-01-09",
      "has_results": true,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541628"
    },
    {
      "nct_id": "NCT07332000",
      "title": "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Patients Treated by Radiotherapy",
        "Prostate Cancer (Adenocarcinoma)"
      ],
      "interventions": [
        {
          "name": "aglatimagene besadenovec + valacyclovir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy (EBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2025-10-30",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 7,
      "location_summary": "Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332000"
    },
    {
      "nct_id": "NCT03893071",
      "title": "Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Niemann-Pick Disease, Type C1"
      ],
      "interventions": [
        {
          "name": "Hydroxypropyl-β-cyclodextrin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyclo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-05-23",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893071"
    },
    {
      "nct_id": "NCT06976736",
      "title": "A Long Term Follow-up Study of TScan TCR-T Products",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AML",
        "ALL",
        "MDS"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2025-09-09",
      "completion_date": "2040-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 2,
      "location_summary": "Duarte, California • New York, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06976736"
    },
    {
      "nct_id": "NCT06326411",
      "title": "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oncology",
        "MEK Mutation",
        "RAF Gene Mutation",
        "Ras (KRAS or NRAS) Gene Mutation",
        "Melanoma",
        "NSCLC",
        "Glioma",
        "Solid Tumor, Adult",
        "MAPK Pathway Gene Mutation"
      ],
      "interventions": [
        {
          "name": "NST-628",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nested Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2024-04-09",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-09T03:58:23.643Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Westwood, Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06326411"
    }
  ]
}